NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT), a leading bio-therapeutics Company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of malignant, ischemic and autoimmune disorders, announced today that it will present its clinical trial plans at the Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California, USA. The presentation will take place on February 19th at 1 pm Pacific Time and will be web-cast live (at http://wsw.com/webcast/roth16/psti/) and for 90 days following the presentation.
